MED
Mark your calendar
Medifast is heading back to the earnings stage on Monday, April 27, after the market closes. And unlike a surprise concert drop, this one comes with a pretty clear set list: analysts are looking for a $0.55 loss per share on $69.2 million in revenue.
Not exactly a victory lap
The company’s own guidance isn’t exactly whispering “turnaround” either. For FY 2026, Medifast sees EPS landing somewhere between -2.75 and -1.55, while Q1 guidance points to a loss of -0.70 to -0.15 per share.
That’s the kind of backdrop that makes every quarter feel like a referendum on whether the weight-loss-and-wellness machine is stabilizing or still losing steam. Investors will be listening for any sign that demand is improving faster than the spreadsheet says it should.
The market’s still side-eyeing this one
Wall Street isn’t throwing confetti either. MarketBeat’s average rating sits at Reduce, with a $12 consensus target, which is basically the market’s way of saying, “show me first.”
Big picture: Medifast doesn’t need a perfect quarter as much as it needs proof that the business is bending in the right direction. If Monday’s report hints at that, the stock could finally get some oxygen.